Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses SDGR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SDGR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ramy Farid | $730,000 | $0 | $796,500 | $1,966,876 | $570,860 | $0 | $14,807 | $4,079,043 |
| President and Chief Executive Officer | ||||||||
| Karen Akinsanya | 600,000 | 0 | 331,875 | 834,824 | 331,200 | 0 | 13,025 | 2,110,924 |
| President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | ||||||||
| Geoffrey Porges | 317,714 | 0 | 265,500 | 667,860 | 0 | 0 | 770,837 | 2,021,911 |
| Former Executive Vice President, Chief Financial Officer | ||||||||
| Mannix Aklian | 286,685 | 75,000 | 301,511 | 1,153,675 | 180,034 | 0 | 14,471 | 2,011,376 |
| Executive Vice President, Chief Commercial Officer, Global Head of Software Sales and Marketing | ||||||||
| Yvonne Tran | 584,000 | 0 | 265,500 | 667,859 | 268,640 | 0 | 14,807 | 1,800,806 |
| Executive Vice President, Chief Legal Officer and Chief People Officer | ||||||||
| Richie Jain | 503,747 | 0 | 588,513 | 459,462 | 231,901 | 0 | 12,306 | 1,795,930 |
| Executive Vice President, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Ramy Farid | $4,079,043 | $4,407,100 | $3,124,165 | −328,057 |
| Karen Akinsanya | 2,110,924 | 2,736,718 | 1,680,400 | −625,794 |
| Geoffrey Porges | 2,021,911 | 2,392,361 | 1,651,742 | −370,450 |
| Mannix Aklian | 2,011,376 | — | — | — |
| Yvonne Tran | 1,800,806 | — | — | — |
| Richie Jain | 1,795,930 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Nancy A. Thornberry | Director | 2026-06-22 | A | 8,141 | $0 | $0 | Common | Form 4 ↗ |
| Jeffrey A. Chodakewitz | Director | 2026-06-22 | A | 13,313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arun Oberoi | Director | 2026-06-22 | A | 8,141 | 0 | 0 | Common | Form 4 ↗ |
| Richard A. Friesner | Director | 2026-06-22 | A | 13,313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Lynton | Director | 2026-06-22 | A | 13,313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arun Oberoi | Director | 2026-06-22 | A | 13,313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey A. Chodakewitz | Director | 2026-06-22 | A | 8,141 | 0 | 0 | Common | Form 4 ↗ |
| Richard A. Friesner | Director | 2026-06-22 | A | 8,141 | 0 | 0 | Common | Form 4 ↗ |
| Gary Ginsberg | Director | 2026-06-22 | A | 8,141 | 0 | 0 | Common | Form 4 ↗ |
| Rosana Kapeller-Libermann | Director | 2026-06-22 | A | 8,141 | 0 | 0 | Common | Form 4 ↗ |
| Rosana Kapeller-Libermann | Director | 2026-06-22 | A | 13,313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Lynton | Director | 2026-06-22 | A | 8,141 | 0 | 0 | Common | Form 4 ↗ |
| Gary Sender | Director | 2026-06-22 | A | 8,141 | 0 | 0 | Common | Form 4 ↗ |
| Gary Sender | Director | 2026-06-22 | A | 13,313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy A. Thornberry | Director | 2026-06-22 | A | 13,313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bridget van Kralingen | Director | 2026-06-22 | A | 8,141 | 0 | 0 | Common | Form 4 ↗ |
| Bridget van Kralingen | Director | 2026-06-22 | A | 13,313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary Ginsberg | Director | 2026-06-22 | A | 13,313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard A. Friesner | Director | 2026-06-26 | D | 679,373 | 0 | 0 | Common | Form 4 ↗ |
| Richard A. Friesner | Director | 2026-06-26 | A | 679,373 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Richie Jain | EVP & CFO | 2026-07-16 | D | 875 | 16 | 13,647 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Ramy Farid | OPTION | 2025-03-03 | — | — | 60,000 | — | $801,432 |
| Ramy Farid | OPTION | 2025-03-03 | — | — | 90,000 | — | 1,165,445 |
| Mannix Aklian | OPTION | 2025-05-29 | — | — | 84,375 | — | 1,153,676 |
| Geoffrey Porges | OPTION | 2025-03-03 | — | — | 50,000 | — | 667,860 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Ramy Farid | $0 | $0 | $1,966,877 | 0.0% |
| Mannix Aklian | 0 | 0 | 1,153,676 | 0.0% |
| Geoffrey Porges | 0 | 0 | 667,860 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Richie Jain | RSU | 18,655 | — | $333,551 |
| Karen Akinsanya | PSU | 7,813 | — | 139,696 |
| Yvonne Tran | RSU | 3,795 | — | 67,855 |
| Karen Akinsanya | Option | 3,334 | 27.76 | — |
| Karen Akinsanya | Option | 18,454 | 23.29 | — |
| Mannix Aklian | Option | 84,375 | 21.44 | — |
| Karen Akinsanya | RSU | 27,576 | — | 493,059 |
| Ramy Farid | RSU | 37,500 | — | 670,500 |
| Yvonne Tran | PSU | 6,250 | — | 111,750 |
| Yvonne Tran | Option | 33,750 | 25.24 | — |
| Yvonne Tran | RSU | 13,788 | — | 246,529 |
| Yvonne Tran | Option | 13,279 | 23.29 | — |
| Ramy Farid | RSU | 48,259 | — | 862,871 |
| Ramy Farid | Option | 8,959 | 27.76 | — |
| Richie Jain | Option | 15,990 | 21.24 | — |
| Ramy Farid | Option | 60,000 | 21.24 | — |
| Karen Akinsanya | Option | 62,500 | 21.24 | — |
| Mannix Aklian | RSU | 14,063 | — | 251,446 |
| Ramy Farid | Option | 70,875 | 25.24 | — |
| Ramy Farid | Option | 49,090 | 27.76 | — |
| Ramy Farid | Option | 90,000 | 23.36 | — |
| Richie Jain | Option | 18,959 | 26.04 | — |
| Karen Akinsanya | Option | 67,500 | 25.24 | — |
| Yvonne Tran | RSU | 12,500 | — | 223,500 |
| Yvonne Tran | Option | 2,500 | 27.76 | — |
| Ramy Farid | PSU | 18,750 | — | 335,250 |
| Richie Jain | Option | 18,750 | 20.51 | — |
| Richie Jain | RSU | 9,375 | — | 167,625 |
| Karen Akinsanya | RSU | 15,625 | — | 279,375 |
| Richie Jain | RSU | 7,500 | — | 134,100 |
| Ramy Farid | Option | 24,780 | 23.29 | — |
| Ramy Farid | Option | 19,112 | 25.62 | — |
| Yvonne Tran | Option | 50,000 | 21.24 | — |
Our compensation and benefits philosophy and the overall structure of our compensation and benefit programs are broadly similar across the organization to encourage and reward all employees who contribute to our success. We strive to ensure that the compensation of every Schrödinger employee reflects the level of their job impact and their responsibilities and is competitive within our peer group. Compensation rates are benchmarked and are generally set to be market-competitive in the country in which the jobs are performed.
| CEO STI target (% of salary) | 85% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-23 | 51,345,375 | 870,926 | 75,635 | 98.33% | Passed |
| 2025 | 2025-06-18 | 50,758,151 | 3,028,650 | 48,516 | 94.37% | Passed |
| 2024 | 2024-06-18 | 52,049,253 | 1,024,272 | 91,849 | 98.07% | Passed |
| 2023 | 2023-06-15 | 50,228,778 | 2,863,662 | 203,378 | 94.61% | Passed |
| 2022 | 2022-06-15 | 44,028,643 | 2,950,386 | 47,876 | 93.72% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-23 | 98.33%a |
| 2025 | 2025-06-18 | 94.37%b |
| 2024 | 2024-06-18 | 98.07%c |
a. Approved under the standard stated in the filing — “4 Abstentions and broker non-votes count as present for establishing a quorum but will not be counted as votes cast.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes count as present for establishing a quorum but will not be counted as votes cast.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes count as present for establishing a quorum but will not be counted as votes cast.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 23 : 1 |
|---|---|
| CEO total compensation | $4,079,043 |
| Median employee compensation | $179,327 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Richard A. FriesnerNot independent | $50,000 | $126,237 | $126,249 | $0 | $0 | $739,286 |
| Bridget van KralingenIndependent · Newly elected | 40,972 | 241,754 | 257,456 | 0 | 0 | 540,183 |
| Michael LyntonIndependent · Board Chair · Audit · Nominating/Governance (Chair) | 110,000 | 126,237 | 126,249 | 0 | 0 | 362,486 |
| Gary SenderIndependent · Audit (Chair) · Compensation (Chair) | 85,000 | 126,237 | 126,249 | 0 | 0 | 337,486 |
| Jeffrey A. ChodakewitzIndependent · Drug Discovery (Chair) · Nominating/Governance | 70,000 | 126,237 | 126,249 | 0 | 0 | 322,486 |
| Gary GinsbergIndependent · Audit · Compensation | 67,500 | 126,237 | 126,249 | 0 | 0 | 319,986 |
| Rosana Kapeller-LibermannIndependent · Compensation · Drug Discovery | 65,000 | 126,237 | 126,249 | 0 | 0 | 317,486 |
| Nancy A. ThornberryIndependent · Nominating/Governance · Drug Discovery | 62,500 | 126,237 | 126,249 | 0 | 0 | 314,986 |
| Arun OberoiIndependent · Audit | 60,000 | 126,237 | 126,249 | 0 | 0 | 312,486 |
| Ramy FaridEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $252,486 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $610,972 |
| Equity awards (grant-date value) | $1,251,650 |
| All other compensation | $0 |
| Total cost of the board | $1,862,622 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Schrodinger, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Schrodinger, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | $1,000,000 | $19,350,145 | $1,650,014 | $1,147,500 | $23,166,223 |
| 2 | Doximity, Inc. | 2026 | Jeff Tangney | 627,000 | 18,955,899 | 0 | 0 | 19,586,169 |
| 3 | BridgeBio Pharma, Inc. | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 4 | Twist Bioscience Corp. | 2025 | Emily Leproust | 720,000 | 11,998,134 | 0 | 932,918 | 13,781,570 |
| 5 | Blueprint Medicines Corp. | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 6 | Ionis Pharmaceuticals | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 7 | Azenta, Inc. | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 8 | Adaptive Biotechnologies Corp. | 2025 | Chad Robins | 698,258 | 7,675,100 | 0 | 703,380 | 9,081,690 |
| 9 | Zuora Inc. | 2024 | Tien Tzuo | 500,000 | 7,950,000 | 0 | 337,500 | 8,787,500 |
| 10 | Yext, Inc. | 2026 | Michael Walrath | 482,308 | 7,675,000 | 0 | 503,608 | 8,693,973 |
| 11 | Inspire Medical Systems, Inc. | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 12 | CRISPR Therapeutics AG | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 13 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 14 | Certara, Inc. | 2025 | William Feehery | 795,675 | 4,927,502 | 0 | 747,935 | 6,491,387 |
| 15 | 10x Genomics, Inc. | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 16 | Ginkgo Bioworks Holdings, Inc. | 2025 | Jason Kelly | 250,000 | 5,454,049 | 0 | 0 | 5,709,049 |
| 17 | Recursion Pharmaceuticals, Inc. | 2025 | Najat Khan | 600,000 | 1,944,547 | 2,501,058 | 256,777 | 5,349,065 |
| 18 | Quanterix Corporation | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 19 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 20 | Pacific Biosciences of California | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 21 | Schrodinger, Inc. | 2025 | Ramy Farid | 730,000 | 796,500 | 1,966,876 | 570,860 | 4,079,043 |
| 22 | Appian Corporation | 2025 | Matthew Calkins | 1,150,000 | 1,760,000 | 0 | 0 | 2,941,276 |
| — | Veradigm Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Schrodinger, Inc. | 92% | not disclosed | No | Aon |
| 10x Genomics, Inc. | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Adaptive Biotechnologies Corp. | 100% | RSU 50 · PSU 50 | No | Semler Brossy Consulting Group, LLC |
| Appian Corporation | not disclosed | RSU 100 | No | not disclosed |
| Azenta, Inc. | 107.4% | PSU 50 · RSU 50 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| Blueprint Medicines Corp. | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon (Human Capital Solutions practice, formerly Radford) |
| BridgeBio Pharma, Inc. | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Certara, Inc. | 94% | PSU 60 · RSU 40 | Yes — annualized total stockholder return (ATSR) | Meridian Compensation Partners |
| CRISPR Therapeutics AG | 122.5% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Doximity, Inc. | not disclosed | not disclosed | No | Aon plc (Human Capital Solutions Practice) |
| Ginkgo Bioworks Holdings, Inc. | not disclosed | not disclosed | No | Alpine Rewards |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Inspire Medical Systems, Inc. | 111.4% | PSU 50 · RSU 50 | No | Aon |
| Ionis Pharmaceuticals | 228% | RSU 67 · PSU 33 | Yes — Relative TSR | Aon Human Capital Solutions |
| Pacific Biosciences of California | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Quanterix Corporation | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| Recursion Pharmaceuticals, Inc. | 80% | RSU 50 · Options 50 | not disclosed | Compensia |
| Twist Bioscience Corp. | 129.6% | PSU 50 · RSU 50 | No | not disclosed |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
| Veradigm Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Yext, Inc. | 102.83% | RSU 50 · PSU 50 | No | Compensia |
| Zuora Inc. | 67.5% | not disclosed | No | Compensia |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Ramy Farid | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Summary Compensation Table”. As printed: 4,079,043. Filing ↗machine: span 722763–722772 |
| 2 | Section 01, Karen Akinsanya | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Summary Compensation Table”. As printed: 2,110,924. Filing ↗machine: span 745713–745722 |
| 3 | Section 01, Geoffrey Porges | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Summary Compensation Table”. As printed: 2,021,911. Filing ↗machine: span 735838–735847 |
| 4 | Section 01, Mannix Aklian | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Summary Compensation Table”. As printed: 2,011,376. Filing ↗machine: span 755465–755474 |
| 5 | Section 01, Yvonne Tran | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Summary Compensation Table”. As printed: 1,800,806. Filing ↗machine: span 758738–758747 |
| 6 | Section 01, Richie Jain | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Summary Compensation Table”. As printed: 1,795,930. Filing ↗machine: span 732110–732119 |
| 7 | Section 03, Ramy Farid OPTION | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t37 · r4 · c18 · span 915085–915092 |
| 8 | Section 03, Ramy Farid OPTION | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t37 · r5 · c18 · span 918992–919001 |
| 9 | Section 03, Mannix Aklian OPTION | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t37 · r22 · c18 · span 984197–984206 |
| 10 | Section 03, Geoffrey Porges OPTION | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t37 · r14 · c18 · span 953438–953445 |
| 11 | Section 07, pay ratio | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “CEO Pay Ratio”. As printed: 23 : 1. Filing ↗machine: span 774371–774373 |
| 12 | Section 08, Richard A. Friesner | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Director Compensation”. As printed: 739,286. Filing ↗machine: t43 · r4 · c14 · span 1263572–1263579 |
| 13 | Section 08, Bridget van Kralingen | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Director Compensation”. As printed: 540,183. Filing ↗machine: t43 · r10 · c14 · span 1277398–1277405 |
| 14 | Section 08, Michael Lynton | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Director Compensation”. As printed: 362,486. Filing ↗machine: t43 · r2 · c14 · span 1258759–1258766 |
| 15 | Section 08, Gary Sender | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Director Compensation”. As printed: 337,486. Filing ↗machine: t43 · r8 · c14 · span 1272785–1272792 |
| 16 | Section 08, Jeffrey A. Chodakewitz | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Director Compensation”. As printed: 322,486. Filing ↗machine: t43 · r3 · c14 · span 1261095–1261102 |
| 17 | Section 08, Gary Ginsberg | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Director Compensation”. As printed: 319,986. Filing ↗machine: t43 · r5 · c14 · span 1265870–1265877 |
| 18 | Section 08, Rosana Kapeller-Libermann | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Director Compensation”. As printed: 317,486. Filing ↗machine: t43 · r6 · c14 · span 1268193–1268200 |
| 19 | Section 08, Nancy A. Thornberry | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Director Compensation”. As printed: 314,986. Filing ↗machine: t43 · r9 · c14 · span 1275089–1275096 |
| 20 | Section 08, Arun Oberoi | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Director Compensation”. As printed: 312,486. Filing ↗machine: t43 · r7 · c14 · span 1270489–1270496 |
| 21 | Section 08, Ramy Farid | DEF 14A | 2026-04-28 | 0001490978-26-000026 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 02, Nancy A. Thornberry 2026-06-22 | Form 4 | 2026-06-23 | 0001797826-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Jeffrey A. Chodakewitz 2026-06-22 | Form 4 | 2026-06-23 | 0001610876-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Arun Oberoi 2026-06-22 | Form 4 | 2026-06-23 | 0001490978-26-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Richard A. Friesner 2026-06-22 | Form 4 | 2026-06-23 | 0001798426-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Michael Lynton 2026-06-22 | Form 4 | 2026-06-23 | 0001606115-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Arun Oberoi 2026-06-22 | Form 4 | 2026-06-23 | 0001490978-26-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Jeffrey A. Chodakewitz 2026-06-22 | Form 4 | 2026-06-23 | 0001610876-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Richard A. Friesner 2026-06-22 | Form 4 | 2026-06-23 | 0001798426-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Gary Ginsberg 2026-06-22 | Form 4 | 2026-06-23 | 0001236136-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Rosana Kapeller-Libermann 2026-06-22 | Form 4 | 2026-06-23 | 0001797835-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Rosana Kapeller-Libermann 2026-06-22 | Form 4 | 2026-06-23 | 0001797835-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Michael Lynton 2026-06-22 | Form 4 | 2026-06-23 | 0001606115-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Gary Sender 2026-06-22 | Form 4 | 2026-06-23 | 0001659085-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Gary Sender 2026-06-22 | Form 4 | 2026-06-23 | 0001659085-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Nancy A. Thornberry 2026-06-22 | Form 4 | 2026-06-23 | 0001797826-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Bridget van Kralingen 2026-06-22 | Form 4 | 2026-06-23 | 0001538977-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Bridget van Kralingen 2026-06-22 | Form 4 | 2026-06-23 | 0001538977-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Gary Ginsberg 2026-06-22 | Form 4 | 2026-06-23 | 0001236136-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Richard A. Friesner 2026-06-26 | Form 4 | 2026-06-29 | 0001798426-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Richard A. Friesner 2026-06-26 | Form 4 | 2026-06-29 | 0001798426-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Richie Jain 2026-07-16 | Form 4 | 2026-07-17 | 0002068195-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 06, 2026 vote | Form 8-K | 2026-06-23 | 0001490978-26-000049 | Item 5.07 · say-on-pay result. As reported: 98.33% (votes for as printed: 51,345,375). Filing ↗ |
| 44 | Section 06, 2025 vote | Form 8-K | 2025-06-18 | 0001490978-25-000082 | Item 5.07 · say-on-pay result. As reported: 94.37% (votes for as printed: 50,758,151). Filing ↗ |
| 45 | Section 06, 2024 vote | Form 8-K | 2024-06-18 | 0001490978-24-000051 | Item 5.07 · say-on-pay result. As reported: 98.07% (votes for as printed: 52,049,253). Filing ↗ |
| 46 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 47 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 48 | Section 09b board cost (computed) | Computed | — | computed | Cash 610,972 + equity 1,251,650 + all other 0 = 1,862,622, summed across the director compensation table rows.machine: formula: Σ = 1,862,622 |
| 49 | Halozyme Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 50 | Doximity, Inc., Section 10b CEO total | DEF 14A | 2026-07-15 | 0001516513-26-000032 | CEO total compensation as printed in Doximity, Inc.'s own proxy. As printed: 19,586,169. Filing ↗machine: span 468084–468094 |
| 51 | BridgeBio Pharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 52 | Twist Bioscience Corp., Section 10b CEO total | DEF 14A | 2026-01-06 | 0001581280-26-000006 | CEO total compensation as printed in Twist Bioscience Corp.'s own proxy. As printed: 13,781,570. Filing ↗machine: t34 · r2 · c15 · span 1510951–1510961 |
| 53 | Blueprint Medicines Corp., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines Corp.'s own proxy. As printed: 13,477,004. Filing ↗machine: t150 · r5 · c14 · span 1101152–1101162 |
| 54 | Ionis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗machine: t325 · r3 · c25 · span 1543650–1543661 |
| 55 | Azenta, Inc., Section 10b CEO total | DEF 14A | 2025-12-18 | 0001140361-25-046064 | CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129 |
| 56 | Adaptive Biotechnologies Corp., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177409 | CEO total compensation as printed in Adaptive Biotechnologies Corp.'s own proxy. As printed: 9,081,690. Filing ↗machine: span 818708–818717 |
| 57 | Zuora Inc., Section 10b CEO total | DEF 14A | 2024-05-16 | 0001423774-24-000146 | CEO total compensation as printed in Zuora Inc.'s own proxy. As printed: 8,787,500. Filing ↗machine: r2 · c42 · span 699493–699502 |
| 58 | Yext, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027491 | CEO total compensation as printed in Yext, Inc.'s own proxy. As printed: 8,693,973. Filing ↗machine: t15 · r2 · c19 · span 368568–368577 |
| 59 | Inspire Medical Systems, Inc., Section 10b CEO total | DEF 14A | 2026-03-20 | 0001140361-26-010490 | CEO total compensation as printed in Inspire Medical Systems, Inc.'s own proxy. As printed: 7,711,784. Filing ↗machine: r2 · c25 · span 1164868–1164877 |
| 60 | CRISPR Therapeutics AG, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001193125-26-165158 | CEO total compensation as printed in CRISPR Therapeutics AG's own proxy. As printed: 7,678,477. Filing ↗machine: t21 · r2 · c26 · span 821649–821658 |
| 61 | Veracyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001384101-26-000021 | CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422 |
| 62 | Certara, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039372 | CEO total compensation as printed in Certara, Inc.'s own proxy. As printed: 6,491,387. Filing ↗machine: r1 · c42 · span 883232–883241 |
| 63 | 10x Genomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027201 | CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292 |
| 64 | Ginkgo Bioworks Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028377 | CEO total compensation as printed in Ginkgo Bioworks Holdings, Inc.'s own proxy. As printed: 5,709,049. Filing ↗machine: r2 · c18 · span 453326–453335 |
| 65 | Recursion Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001601830-26-000065 | CEO total compensation as printed in Recursion Pharmaceuticals, Inc.'s own proxy. As printed: 5,349,065. Filing ↗machine: t130 · r5 · c13 · span 551909–551918 |
| 66 | Quanterix Corporation, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001104659-26-048166 | CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. Filing ↗machine: t18 · r1 · c47 · span 503076–503085 |
| 67 | Denali Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 68 | Pacific Biosciences of California, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001299130-26-000064 | CEO total compensation as printed in Pacific Biosciences of California's own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983 |
| 69 | Schrodinger, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001490978-26-000026 | CEO total compensation as printed in Schrodinger, Inc.'s own proxy. As printed: 4,079,043. Filing ↗machine: span 722763–722772 |
| 70 | Appian Corporation, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001441683-26-000021 | CEO total compensation as printed in Appian Corporation's own proxy. As printed: 2,941,276. Filing ↗machine: r2 · c42 · span 416139–416148 |
| 71 | Section 10a, BridgeBio Pharma, Inc. reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharma, Inc.'s most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 72 | Section 10a, Denali Therapeutics Inc. reciprocity | DEF 14A | — | 0001714899-26-000054 | Denali Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 73 | Section 10a, Ionis Pharmaceuticals reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 74 | Section 10a, Halozyme Therapeutics, Inc. reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 75 | Section 10a, Adaptive Biotechnologies Corp. reciprocity | DEF 14A | — | 0001193125-26-177409 | Adaptive Biotechnologies Corp.'s most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 76 | Section 10a, Azenta, Inc. reciprocity | DEF 14A | — | 0001140361-25-046064 | Azenta, Inc.'s most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 77 | Section 10a, CRISPR Therapeutics AG reciprocity | DEF 14A | — | 0001193125-26-165158 | CRISPR Therapeutics AG's most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 78 | Section 10a, Doximity, Inc. reciprocity | DEF 14A | — | 0001516513-26-000032 | Doximity, Inc.'s most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 79 | Section 10a, Pacific Biosciences of California reciprocity | DEF 14A | — | 0001299130-26-000064 | Pacific Biosciences of California's most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 80 | Section 10a, Certara, Inc. reciprocity | DEF 14A | — | 0001104659-26-039372 | Certara, Inc. names Schrodinger, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 81 | Section 10a, 10x Genomics, Inc. reciprocity | DEF 14A | — | 0001628280-26-027201 | 10x Genomics, Inc.'s most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 82 | Section 10a, Blueprint Medicines Corp. reciprocity | DEF 14A | — | 0001558370-25-005415 | Blueprint Medicines Corp.'s most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 83 | Section 10a, Inspire Medical Systems, Inc. reciprocity | DEF 14A | — | 0001140361-26-010490 | Inspire Medical Systems, Inc.'s most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 84 | Section 10a, Quanterix Corporation reciprocity | DEF 14A | — | 0001104659-26-048166 | Quanterix Corporation's most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 85 | Section 10a, Veracyte, Inc. reciprocity | DEF 14A | — | 0001384101-26-000021 | Veracyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |
| 86 | Section 10a, Zuora Inc. reciprocity | DEF 14A | — | 0001423774-24-000146 | Zuora Inc.'s most recent proxy was read; its disclosed peer group does not include Schrodinger, Inc.. Filing ↗ |